Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26114309 | 1.00 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL30959624 | 0.86 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL26116736 | 0.84 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9AMAPK1MAPT | |
| SCHEMBL30587291 | 0.84 | ALDH1A1 (0.36) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL30587219 | 0.84 | MEN1 (0.34) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL26118191 | 0.84 | MEN1 (0.34) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL31085613 | 0.76 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL23496853 | 0.74 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL29813201 | 0.74 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9AALOX15MAPK1 | |
| SCHEMBL30781859 | 0.74 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9AALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025072457-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250101043-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-03-27 | — | — | US | disclosed |
| WO-2025049274-A2 | TETRACYCLIC DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-4499233-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| US-20240343736-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | disclosed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024206747-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2023183585-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | ALDH1A1 2624/4885NPC1 1188/4885RAB9A 36/4885 |
| US-20240343736-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2134/4885NPC1 1419/4885RAB9A 41/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2395/4885NPC1 1105/4885RAB9A 39/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2134/4885NPC1 1419/4885RAB9A 41/4885 |
| US-20250101043-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 2134/4885NPC1 1419/4885RAB9A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.